TY - JOUR AB - Improvements in cancer therapy have enabled further insight into the long‑term effects of treatment, including the highly prevalent gonadal failure. The focus of treatment has been shifted to the preservation of fertility, which may be achieved by preventing ovarian toxicity. To this end, new molecular‑targeted agents, including monoclonal antibodies, have been developed and used in a standard procedure for managing different cancers. However, the prolonged antitumor activity of these drugs may cause the emergence of new toxic effects. The aim of the present review was to discuss the leading toxic effect of the anti-angiogenic agent bevacizumab on ovarian function in female patients of reproductive age, which may be observed and expected during in clinical practice. The majority of bevacizumab-induced side effects are expected to be transient and eliminated within the anticipated drug clearance time frame; however, fundamental investigations on these effects are required for generating more evidence-based practice guidelines. AD - Department of Obstetrics and Gynecology, Matsunami General Hospital, Kasamatsu, Gifu 501‑6062, Japan AU - Imai,Atsushi AU - Ichigo,Satoshi AU - Matsunami,Kazutoshi AU - Takagi,Hiroshi AU - Kawabata,Ichiro DA - 2017/06/01 DO - 10.3892/mco.2017.1237 EP - 810 IS - 6 JO - Mol Clin Oncol KW - bevacizumab anti-angiogenic chemotherapy female reproduction ovarian damage PY - 2017 SN - 2049-9450 2049-9469 SP - 807 ST - Ovarian function following targeted anti-angiogenic therapy with bevacizumab (Review) T2 - Molecular and Clinical Oncology TI - Ovarian function following targeted anti-angiogenic therapy with bevacizumab (Review) UR - https://doi.org/10.3892/mco.2017.1237 VL - 6 ER -